Drug intelligence / Profile preview

Ortuzumab

Development stage: Phase 4
Lead developer: Genentech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Ortuzumab is an anti-CD20 monoclonal antibody. It is being investigated in clinical trials for its efficacy and safety in combination with thrombopoietin receptor agonists (TPO-RAs) for the management of pediatric primary immune thrombocytopenia (ITP). The drug is administered via infusion.

Targets

CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on Ortuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ortuzumab.

Explore the full profile